{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon+Beta-1a&page=3",
    "query": {
      "intervention": "Interferon Beta-1a",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 107,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon+Beta-1a&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Interferon+Beta-1a&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T10:22:46.432Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01034579",
      "title": "The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Blood sampling",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2010-02",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2014-03-10",
      "last_synced_at": "2026-10-07T10:22:46.432Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01034579"
    },
    {
      "nct_id": "NCT00428584",
      "title": "RNF and Betaseron® Tolerability Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis (RRMS)"
      ],
      "interventions": [
        {
          "name": "New Formulation of rebif - human interferon beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Interferon beta -1b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 129,
      "start_date": "2006-12",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2013-08-07",
      "last_synced_at": "2026-10-07T10:22:46.432Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428584"
    },
    {
      "nct_id": "NCT00811395",
      "title": "Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for teriflunomide)",
          "type": "DRUG"
        },
        {
          "name": "Interferon-β [IFN-β]",
          "type": "DRUG"
        },
        {
          "name": "Glatiramer Acetate [GA]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 182,
      "start_date": "2007-10",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2012-12-31",
      "last_synced_at": "2026-10-07T10:22:46.432Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811395"
    },
    {
      "nct_id": "NCT00273364",
      "title": "Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Hematopoietic Stem Cell Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Standard treatment with a conventional drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 110,
      "start_date": "2005-11-16",
      "completion_date": "2019-08-30",
      "has_results": true,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-10-07T10:22:46.432Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00273364"
    },
    {
      "nct_id": "NCT02117050",
      "title": "RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Rebif®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2014-06",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2017-01-23",
      "last_synced_at": "2026-10-07T10:22:46.432Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02117050"
    },
    {
      "nct_id": "NCT00210301",
      "title": "Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Provigil (modafinil)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institute for Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "20 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2003-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-09-07",
      "last_synced_at": "2026-10-07T10:22:46.432Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00210301"
    },
    {
      "nct_id": "NCT00599274",
      "title": "Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Interferon beta-1a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 136,
      "start_date": "2002-08",
      "completion_date": "2003-05",
      "has_results": false,
      "last_update_posted_date": "2010-01-27",
      "last_synced_at": "2026-10-07T10:22:46.432Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Walnut Creek, California • Shreveport, Louisiana + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00599274"
    },
    {
      "nct_id": "NCT00223301",
      "title": "Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Mycophenolate Mofetil (cellcept)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2004-07",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2013-04-22",
      "last_synced_at": "2026-10-07T10:22:46.432Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00223301"
    },
    {
      "nct_id": "NCT05688436",
      "title": "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Diroximel Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fingolimod",
          "type": "DRUG"
        },
        {
          "name": "Glatiramer acetate",
          "type": "DRUG"
        },
        {
          "name": "Interferon beta",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Natalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ocrelizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ozanimod",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon beta-1a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ponesimod",
          "type": "DRUG"
        },
        {
          "name": "Siponimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 1178,
      "start_date": "2021-09-24",
      "completion_date": "2031-01-17",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-07T10:22:46.432Z",
      "location_count": 1,
      "location_summary": "Eden Prairie, Minnesota",
      "locations": [
        {
          "city": "Eden Prairie",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05688436"
    },
    {
      "nct_id": "NCT01834586",
      "title": "Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Anesthetic Topical Adhesive Synera",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brown, Theodore R., M.D., MPH",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2013-03",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-10",
      "last_synced_at": "2026-10-07T10:22:46.432Z",
      "location_count": 1,
      "location_summary": "Kirkland, Washington",
      "locations": [
        {
          "city": "Kirkland",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01834586"
    }
  ]
}